Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.
PNC-27
Also known as: p53-derived anticancer peptide
PNC-27 is a synthetic peptide containing a p53 C-terminal fragment linked to a cell-penetrating peptide sequence. It was designed to selectively kill cancer cells by targeting the HDM2 (human double minute 2) protein that is overexpressed on cancer cell membranes. In vitro studies show selective cytotoxicity against various cancer cell lines while sparing normal cells. No human clinical trials exist.
Risk Level
Very High RiskDifficulty
Advanced| Class | Peptide |
| Category | Underground Peptides |
Mechanism of Action
Binds to HDM2 protein on cancer cell surfaces, forming pore-like structures in the cancer cell membrane that lead to membranolysis and necrotic cell death. Normal cells with low surface HDM2 expression are theoretically spared. The selective membrane-disruption mechanism is distinct from conventional apoptosis-inducing cancer therapies.
Dosing Research
No human dosing established. Underground use reports vary widely. In vitro effective concentrations are in the micromolar range. Translation to in vivo dosing is highly uncertain due to bioavailability, distribution, and stability concerns.
Side Effects & Risks
No human safety data whatsoever. Theoretical risks are severe: off-target membrane disruption in normal cells, immune reactions, and unpredictable toxicity. Using an unproven anticancer peptide outside of clinical trials carries extreme risk. This compound should not be self-administered.
Research Studies
Related compounds
Semaglutide
PeptideSemaglutide is a GLP-1 receptor agonist approved for type 2 diabetes (Ozempic) and chronic weight management (Wegovy). Clinical trials demonstrated average weight loss of 15-17% of body weight. It has become one of the most widely discussed medications in modern weight management.
Tirzepatide
PeptideTirzepatide is a dual GLP-1/GIP receptor agonist approved for type 2 diabetes (Mounjaro) and obesity (Zepbound). It has demonstrated unprecedented weight loss efficacy in clinical trials, with participants losing up to 20-25% of body weight. It represents the cutting edge of pharmaceutical weight management.
Liraglutide
PeptideLiraglutide is a GLP-1 receptor agonist approved for type 2 diabetes (Victoza, 1.8 mg) and obesity (Saxenda, 3.0 mg). It was the first GLP-1 agonist approved specifically for weight management. While effective, it has been largely superseded by semaglutide and tirzepatide in terms of weight loss efficacy.
PT-141
PeptidePT-141 (bremelanotide) is a synthetic cyclic heptapeptide melanocortin receptor agonist that was FDA-approved in 2019 as Vyleesi for the treatment of hypoactive sexual desire disorder in premenopausal women. Unlike PDE5 inhibitors, it acts centrally through the melanocortin system to increase sexual desire rather than just facilitating erection mechanics. It is the only FDA-approved on-demand treatment targeting central sexual arousal pathways.
Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.